Using a new type of PET scanner for imaging prostate cancer and related conditions
Clinical Use of a J-PET Scanner Prototype Made of Plastic Scintilators
Jagiellonian University · NCT06242119
This study is testing a new type of PET scanner to see if it can better detect early signs of prostate cancer and related conditions in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Jagiellonian University (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Krakow) |
| Trial ID | NCT06242119 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the clinical application of the J-PET scanner prototype, which utilizes plastic scintillators instead of traditional crystal scintillators for positron emission tomography (PET). The J-PET scanner aims to enhance the sensitivity and accuracy of imaging metabolic changes associated with prostate cancer and other prostatic conditions. Participants will undergo a PET/CT scan as part of their routine clinical care, and the study will assess the scanner's performance in detecting biochemical alterations at an early stage. The research is conducted at the Department of Experimental Particle Physics and Applications at Jagiellonian University in Krakow.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years referred for a PET/CT scan for prostate cancer or related conditions.
Not a fit: Patients who are pregnant, breastfeeding, or have allergies to radiopharmaceuticals may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accessible and cost-effective imaging techniques for early detection of prostate cancer and related conditions.
How similar studies have performed: While traditional PET imaging has been widely studied, the use of plastic scintillators in PET technology is relatively novel and has not been extensively tested in clinical settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The patient is referred for a PET/CT scan, in accordance with recognized indications for examining the entire body. * Age over 18 years * Informed, voluntary consent to participate in the study Exclusion Criteria: * Pregnant women, breastfeeding women * People with a previously diagnosed allergy to radiopharmaceuticals * Age under 18 years * Lack of cooperation with the patient * Lack of informed consent to participate in the study
Where this trial is running
Krakow
- Department of Endocrinology and Nuclear Medicine, University Hospital in Krakow — Krakow, Poland (RECRUITING)
Study contacts
- Principal investigator: Marta Opalinska, MD, PhD — Department of Endocrinology and Nuclear Medicine, University Hospital in Krakow
- Study coordinator: Pawel Moskal, PhD
- Email: p.moskal@uj.edu.pl
- Phone: 800-555-5555
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prostate Cancer, Prostatic Hyperplasia, Prostatic Neoplasms, Prostate Cancer Metastatic, Neuroendocrine Tumors, Neuroendocrine Carcinoma, positronium, PET